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Abstract
Background: Adipocyte fatty acid-binding protein (A-FABP) has been described as a novel adipokine, playing an important
role in the development of metabolic syndrome, type 2 diabetes and atherosclerosis. In this study, we investigated the
relationship between serum levels of A-FABP and the presence and severity of coronary artery disease (CAD) in Chinese
subjects.
Methodology/Principal Findings: Circulating A-FABP level was determined by ELISA in 341 Chinese subjects (221 men, 120
women) who underwent coronary angiography. A-FABP levels in patients with CAD were significantly higher compared
with non-CAD subjects (P=0.029 in men; P=0.031 in women). Serum A-FABP increased significantly in multi-vessel diseased
patients than in non-CAD subjects (P=0.011 in men, P=0.004 in women), and showed an independent correlation with
coronary atherosclerosis index (standardized b=0.173, P=0.025). In multiple logistic regression analysis, serum A-FABP was
an independent risk factor for CAD in women (OR=5.637, 95%CI: 1.299-24.457, P=0.021). In addition, amino terminal pro-
brain natriuretic peptide (NT-proBNP) was demonstrated to be positively and independently correlated with A-FABP
(standardized b=0.135, P=0.027).
Conclusions/Significance: Serum A-FABP is closely associated with the presence and severity of CAD in Chinese women.
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Introduction
Adipose tissue functions as an endocrine organ, secreting a
variety of bioactive substances (called adipokines), which are
actively involved in insulin sensitivity, glucose and lipid metabo-
lism [1]. Adipocyte fatty acid-binding protein (A-FABP, also
known as ap2 and FABP4), a member of the fatty acid binding
protein super family, has recently been described as a novel
adipokine, accounting for approximately 6% of total cellular
proteins in mature adipocytes [2]. It is also present in macro-
phages, which possess similar functions as adipocytes, and
modulated by proliferator-activated receptor-c agonists and
oxidized low density lipoproteins [3].
There is substantial experimental evidence that A-FABP plays
an important role in metabolic deterioration and the development
of atherosclerosis [3]. Mice deficient in A-FABP were protected
from development of insulin resistance, hyperglycemia and
dyslipidemia associated with genetic or diet-induced obesity
[4,5]. A recent study from Furuhashi et al. demonstrated that A-
FABP exerted actions in both adipocytes and macrophages, and
the interactions between these two cell types were critical for the
impact of A-FABP on metabolic deterioration [6]. In apolipopro-
tein E-deficient (apo E
-/-) mice, A-FABP deficiency reduced early
foam cell formation greatly, and provided remarkable protection
against atherosclerosis with significant reductions in mean
atherosclerotic lesion area on a chow diet or a western diet
independent of the effects of A-FABP on insulin resistance and
plasma lipids [7,8]. Moreover, an orally active A-FABP inhibitor
can remarkably prevent atherosclerosis in apo E
-/- mice [9].
Similar to A-FABP deficiency in experimental models, a genetic
variant at A-FABP locus with reduction in A-FABP expression
reduced the risk for cardiovascular disease and type 2 diabetes in a
population genetic study [10].
Although originally identified as a major cytoplasmic protein, A-
FABP is also released from adipose tissue into the circulation [11].
In keeping with the experimental findings, several clinical
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parameters of insulin resistance, adiposity, and hyperglycemia
[11]. Serum A-FABP levels were found to be independently
associated with carotid atherosclerosis in Chinese women [12].
Recent two studies in Korean adults and Chinese found that A-
FABP levels tended to be higher in CAD patients compared to
non-CAD subjects (P=0.096 and P=0.088) [13,14]. Further-
more, both studies have demonstrated significantly higher serum
A-FABP levels in subjects with 3-vessel disease than those without
CAD and those with 1-vessel disease. These observations from
animal models and human suggest A-FABP may be an important
player in the development of CAD. Therefore, this study was
conducted to further explore the role of A-FABP in CAD, and to
determine whether A-FABP influences CAD independent of the
traditional risk factors. In addition, we also measured high
sensitivity C-reactive protein (hsCRP) and amino terminal pro-
brain natriuretic peptide (NT-proBNP), two biomarkers involved
in cardiovascular disease, to investigate the possible mechanisms
mediating the impact of A-FABP on the development of CAD.
Methods
Ethics Statement
All subjects gave written informed consent, and the study was
approved by the ethics committee of Shanghai Jiao Tong
University Affiliated Sixth People’s Hospital and complied with
the Declaration of Helsinki.
Participants
The study population consisted of 341 participants (221 men
and 120 women, aged 66.1610.4 years) who were admitted to the
Department of Cardiology of Shanghai Jiao Tong University
Affiliated Sixth People’s Hospital to undergo coronary angiogra-
phy between July 2008 and October 2009. All women were
postmenopausal. The diagnosis of type 2 diabetes was based on
1999 World Health Organization criteria [15]. According to the
definition of Chinese Joint Committee for Developing Chinese
Guidelines on Prevention and Treatment of Dyslipidemia in
Adults [16], the metabolic syndrome was defined as having $3o f
the following metabolic risk factors: (1) central obesity (waist
circumference .90 cm for men and .85 cm for women), (2)
fasting triglycerides (TG) $1.70 mmol/l, (3) fasting high density
lipoprotein cholesterol (HDL-c) , 1.04 mmol/l, (4) hypertension
(sitting blood pressure $130/85 mm Hg or known treatment for
hypertension), (5) hyperglycemia defined as fasting glucose (FPG)
$6.1 mmol/l and/or 2-h postchallenge glycemia (2hPG)
$7.8 mmol/l or on hypoglycemic therapy for treatment of
diabetes. Medical history, medication history and smoking habits
were assessed using a standardized questionnaire. Those who had
regularly smoked in the past or who smoked at least one cigarette
per day lasting for at least one year were included into the analysis.
Subjects with the following conditions were excluded: hepatic or
renal dysfunction, recent myocardial infarction (,3 months),
previous coronary by-pass surgery or percutaneous coronary
intervention (,6 months), congestive heart failure (New York
Heart Association Class III,IV), acute infection, and history of
malignancy.
Coronary angiography
Coronary angiography was performed using standard Judkins
techniques [17], and all major coronary arteries were carefully
imaged in at least two orthogonal views. Angiographic analysis was
carried out by 2 experienced interventional cardiologists, who
were unaware of clinical information of the patients. CAD was
defined as the presence of 50% or greater coronary diameter
lumen stenosis in a major coronary artery (left main coronary
artery, left anterior descending artery or its first diagonal branch,
left circumflex artery or its first obtuse marginal branch, and right
coronary artery). According to the number of diseased vessels,
CAD patients were further divided into 1-vessel and multi-vessel
disease groups which included patients with 2-vessel and 3-vessel
disease. Left main stenosis $50% was considered as 2-vessel
disease.
The extent and severity of CAD was assessed by assigning points
to each lesion as follows: no significant stenosis of the luminal
diameter, 0; stenosis of less than 25%, 1; 25–49% stenosis, 2; 50–
74%, 3; 75–100%, 4. The coronary atherosclerosis index (CAI)
was defined as the sum of these scores [18].
Anthropometric evaluation
A complete physical examination was performed on each
subject. Body mass index (BMI) was calculated as weight in
kilograms divided by squared height in meters (kg/m
2). Waist
circumference was measured midway between the lowest rib and
the superior border of iliac crest on midaxillary line.
Biochemical assessment
Blood samples were collected after an overnight fast and stored
at 280uC prior to analysis. Subjects without diabetes received a
standard 75 g oral glucose tolerance test. FPG and 2hPG were
determined using glucose oxidase method. Serum insulin was
assayed via radio-immunoassay (Linco Research, St Charles,
Missouri, USA). Glycated hemoglobin A1c (HbA1c) values were
measured by high performance liquid chromatography (Bio-Rad
Laboratories, Hercules, CA, USA). Serum creatinine and lipid
profiles, including total cholesterol (TC), TG, HDL-c and low
density lipoprotein cholesterol (LDL-c) were determined by
enzymatic procedures using an autoanalyser (Hitachi 7600–020;
Hitachi, Tokyo, Japan). Serum hsCRP was measured by a
particle-enhanced immunoturbidimetric assay (Dade Behring
Inc., Newark, USA). NT-proBNP was assayed by chemilumines-
cence (Cobas 6000, Roche Diagnostics GmbH, Mannheim,
Germany). A-FABP levels were assayed by sandwich ELISA
(BioVendor Laboratory Medicine, Modrice, Czech Republic).
Insulin resistance was estimated using homeostasis model assess-
ment index (HOMA-IR) [19]. Renal function was evaluated by
the estimated glomerular filtration rate (GFR) derived from
Cockroft-Gault formula [20].
Statistical analysis
All analyses were performed using SPSS version 13.0 (SPSS,
Chicago, IL). Data were reported as means 6 SD for normal
distributions or median with interquartile range for skewed
variables. Data that were not normally distributed as determined
by the Kolmogorov-Smirnov test were logarithmically transformed
before analysis. Characteristics of subjects between non-CAD and
CAD groups or men and women were compared using unpaired
Student’s t-test (for data that were normally distributed) or the
Mann-Whitney U-test (not normally distributed). One-way
ANOVA was used to compare serum A-FABP levels in groups
according to number of diseased vessels. The chi-square test was
used to compare categorical variables between groups. The
Spearman correlation analysis was used to assess the correlations
of CAI and serum A-FABP with metabolic parameters. To
determine the independent parameters correlated with CAI and
A-FABP, parameters including age, gender, and those correlated
significantly with CAI and A-FABP in correlation analysis were
tested in multiple stepwise regression analysis. Multiple logistic
A-FABP Levels and Coronary Artery Disease
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predictors for CAD. Parameters that significantly different
between subjects with and without CAD and conventional risk
factors including lipid profile (TC, TG, LDL-c, HDL-c) were
selected to enter into multiple logistic regression. Two-sided values
of P,0.05 were considered as statistically significant.
Results
The clinical characteristics of the subjects are shown in Table 1.
Of the 341 subjects, 94 were without CAD (46 men, 48 women),
while 247 suffered from CAD (175 men, 72 women). Patients with
CAD had higher age, HbA1c, NT-proBNP, CAI and the
proportion of statin use, as well as lower GFR compared with
those without CAD in both genders (all P,0.05). Women with
CAD also had significant higher systolic blood pressure, 2hPG and
the percentage of hypertension than non-CAD controls (all
P,0.05).
As shown in Figure 1, serum A-FABP levels were significantly
higher in women than in men in both CAD group (19.0 ng/ml
(11.7–25.9) vs. 8.9 ng/ml (5.3–12.5), P,0.001) and non-CAD
group (14.4 ng/ml (7.4–22.9) vs. 6.5 ng/ml (4.4–10.7), P,0.001).
Also, A-FABP levels in patients with CAD increased significantly
compared with non-CAD subjects in both men and women
(P=0.029 and P=0.031, respectively).
We next analyzed the relationship between serum A-FABP and
the severity of CAD. In all subjects, CAI was positively associated
with age (r=0.371, P,0.001). After adjusting for age and gender,
CAI showed a positive correlation with HbA1c, fasting insulin,
HOMA-IR, NT-proBNP and serum A-FABP (P,0.05), and an
inverse correlation with HDL-c (P=0.029) (Table 2). In multiple
stepwise regression analysis after controlling for age, gender,
HOMA-IR, HbA1c, and HDL-c, A-FABP was shown to be
independently correlated with CAI (standardized b=0.173,
P=0.025). Furthermore, as shown in Figure 2, the serum levels
of A-FABP increased progressively with the increasing number of
Table 1. Characteristics of the subjects according to the presence or absence of CAD.
Men Women
Non-CAD (n=46) CAD(n=175) Non-CAD (n=48) CAD (n=72)




2) 24.464.1 24.563.2 25.164.2 24.262.9
Waist circumference (cm) 91.9611.3 91.469.1 86.3610.1 88.668.2
Systolic BP (mmHg) 132.6620.9 133.9618.5 130.6615.8 138.1618.2
a
Diastolic BP (mmHg) 80.4610.6 77.9610.6 78.3610.3 77.1610.9
FPG (mmol/l) 5.661.0 5.961.4 5.961.7 6.261.7
2hPG (mmol/l) 9.563.9 9.964.2 8.263.9 9.863.7
a
Fasting insulin (mU/l) 17.066.2 25.6610.3 20.169.0 24.1610.6
HbA1c (%) 6.0 (5.6–6.7) 6.2 (5.8–7.0)
a 6.0 (5.7–6.4) 6.4 (5.9–7.1)
a
HOMA-IR 3.8 (3.2–5.7) 4.2 (3.3–6.6) 4.9 (2.7–6.7) 4.8 (3.4–6.9)
TC (mmol/l) 4.261.0 4.161.0 4.961.0 4.561.2
TG (mmol/l) 1.4 (1.1–2.2) 1.5 (1.0–2.0) 1.4 (0.8–2.3) 1.6 (1.2–2.6)
HDL-c (mmol/l) 1.0 (0.8–1.2) 1.0 (0.8–1.2) 1.3 (1.1–1.5) 1.2 (0.9–1.3)
LDL-c (mmol/l) 2.961.0 2.760.9 3.460.9 3.061.1
Creatinine (mmmol/l) 84 (71–93) 84 (75–96) 60 (56–71) 65 (56–77)
GFR (ml/min) 105.5 (84.7–145.1) 93.7 (76.4–114.1)
a 115.2 (84.3–128.4) 97.4 (77.2–127.6)
a
hsCRP (mg/l) 1.9 (0.6–4.6) 1.4 (0.7–4.6) 1.5 (0.3–2.4) 1.5 (0.5–3.5)
NT-proBNP (ng/l) 105.5 (51.8–222.7) 126.2 (62.4–399.2)
a 90.7 (42.6–305.4) 161.3 (94.6–546.0)
a
CAI 0.0 (0.0–1.0) 10.0 (6.0–15.0)
b 0 (0–0.8) 8 (4.3–13.8)
b
Metabolic syndrome (%) 64.3 60.1 54.5 66.2
Central obesity (%) 48.8 59.2 57.8 64.3
Hyperglycemia (%) 67.4 64.0 50.0 61.1
Hypertriglyceridemia (%) 44.4 38.5 48.9 47.1
Low HDL-c (%) 55.6 57.4 23.4 37.1
Hypertension (%) 82.6 77.1 70.8 86.1
a
Smoking (%) 76.1 65.1 2.1 2.8
Statins use (%) 8.7 32.6
b 12.5 31.9
a
Data are means 6 SD or median (interquartile range). BMI: body mass index; BP, blood pressure; CAI: coronary atherosclerosis index; FPG: fasting plasma glucose; 2hPG:
2-h postchallenge glycemia; GFR: glomerular filtration rate; HbA1c: glycated hemoglobin A1c; HDL-c: high density lipoprotein cholesterol; HOMA-IR: homeostasis model
assessment index of insulin resistance; hsCRP: high sensitivity C-reactive protein; LDL-c: low density lipoprotein cholesterol; NT-proBNP: amino terminal pro-brain
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Compared with those without CAD, patients with multi-vessel
disease had significantly higher serum A-FABP levels in both men
(P=0.011) and women (P=0.004). In addition, significant higher
levels of A-FABP were also observed in women with multi-vessel
disease compared with those with 1 vessel disease (P=0.031).
To evaluate the relationship between A-FABP and CAD,
multiple logistic regression analysis was performed using the
presence of CAD as a dependent variable (Table 3). The analysis
involved age, systolic blood pressure, 2hPG, HbA1c, lipid profile
(TC, TG, LDL-c, HDL-c), GFR, NT-proBNP and A-FABP. As a
result, serum A-FABP (OR=5.637, 95%CI: 1.299–24.457,
P=0.021) and systolic blood pressure (OR=1.075, 95%CI:
1.017–1.137, P=0.010) were demonstrated to be independent
factors for CAD in women. However in men, only age was
independently associated with the presence of CAD (OR=1.066,
95%CI: 1.007–1.128, P=0.029).
A-FABP showed significant positive correlations with age, BMI,
waist circumference, 2hPG, HOMA-IR, creatinine, hsCRP, and
NT-proBNP, and a negative correlation with GFR in both genders
(all P,0.05) (Table 4). A-FABP also correlated with FPG, HbA1c,
fasting insulin, and HDL-c in men as well as LDL-c in women (all
P,0.05). To further determine which variables were indepen-
dently correlated with serum A-FABP, multiple stepwise regression
analysis was performed in all subjects (Table 5). The analysis
involved age, gender, waist circumference, FPG, 2hPG, HbA1c,
HOMA-IR, lipid profile, GFR, hsCRP, and NT-proBNP. As a
Figure 1. Serum A-FABP levels in subjects with and without
CAD. Data are median with interquartile range. Black, men;
white, women. * P,0.001 versus men. # P,0.05 versus non-CAD
group.
doi:10.1371/journal.pone.0019115.g001
Figure 2. Comparison of serum A-FABP levels among groups
with different numbers of diseased vessels. * P,0.05, ** P,0.01
versus non-CAD group. # P,0.05 versus 1 vessel diseased group.
White, non-CAD group; Grey, 1 vessel diseased group; Black, multi-
vessel diseased group. The median A-FABP levels were 7.2 ng/ml (4.5–
11.5) and 9.8 ng/ml (5.9–14.0) for men with 1 and multi-vessel disease
(n=56 and 119), and 15.0 ng/ml (10.5–21.7) and 21.43 ng/ml (16.0–
36.8) for women (n=35 and 37), respectively.
doi:10.1371/journal.pone.0019115.g002
Table 2. Correlation of CAI with cardiometabolic risk factors.
CAI (age and gender adjusted)
r P
BMI 0.044 NS
Waist circumference 20.049 NS
Systolic BP 0.074 NS














A-FABP: Adipocyte fatty acid-binding protein; BMI: body mass index; BP, blood
pressure; CAI: coronary atherosclerosis index; FPG: fasting plasma glucose;
2hPG: 2-h postchallenge glycemia; HbA1c: glycated hemoglobin A1c; HDL-c:
high density lipoprotein cholesterol; HOMA-IR: homeostasis model assessment
index of insulin resistance; hsCRP: high sensitivity C-reactive protein; LDL-c: low
density lipoprotein cholesterol; NT-proBNP: amino terminal pro-brain natriuretic
peptide; TC: total cholesterol; TG: triglyceride.
NS, Not significant.
doi:10.1371/journal.pone.0019115.t002
Table 3. Multivariate logistic regression analysis showing the
parameters independently associated with CAD.
B S.E. P OR 95% CI
Women only (n=120)
A-FABP
a 1.729 0.749 0.021 5.637 1.299–24.457
Systolic BP 0.073 0.028 0.010 1.075 1.017–1.137
Men only (n=221)
Age 0.064 0.029 0.029 1.066 1.007–1.128
aLogarithmically transformed before analysis.
Variables included in the original model are age, systolic BP, 2hPG, HbA1c, TC,
TG, LDL-c, HDL-c, GFR, NT-proBNP and A-FABP.
doi:10.1371/journal.pone.0019115.t003
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LDL-c, GFR and NT-proBNP were independently correlated with
A-FABP (all P,0.05).
Discussion
In the current study, we provided the clinical evidence showing
that A-FABP was closely associated with the severity of coronary
atherosclerosis, and was a significant risk factor for the
development of CAD in women. Furthermore, we found a close
relationship of serum A-FABP with NT-proBNP in both genders.
The relationship of A-FABP with metabolic disease has been
well demonstrated in several clinical studies, which might partly
explain the impact of A-FABP on CAD. Xu et al. demonstrated
that A-FABP levels were not only associated with insulin
resistance, adiposity, dyslipidemia and glucose tolerance param-
eters, but also predicted the development of the metabolic
syndrome and type 2 diabetes in 5-year and 10-year prospective
studies [11,21,22]. In agreement with these findings, we found that
waist circumference, HbA1c, LDL-c and HOMA-IR were
independently associated with serum A-FABP. The mechanism
of these associations has been investigated in several studies. A-
FABP is capable of binding to various intracellular hydrophobic
compounds such as saturated and unsaturated long-chain fatty
acids, modulating cholesterol ester accumulation, and mediating
intracellular lipid trafficking, thus altering cellular and systemic
lipid transport and composition, as well as contributing to
dyslipidemia [23,24]. In skeletal muscle, insulin receptor phos-
phorylation and AMP-activated kinase activity were found to be
enhanced in A-FABP deficient models, thus resulting in enhanced
insulin signaling and fatty acid oxidation [23]. Insulin resistance
has been verified to be closely associated with atherosclerosis, and
the metabolic syndrome is being increasingly recognized to be an
important risk factor for cardiovascular disease. An 11-year
prospective study in a population-based cohort of middle-aged
Finnish men suggested that the metabolic syndrome was associated
with a nearly 3 fold higher mortality from CAD [25]. Therefore,
the association of serum A-FABP with CAD might be partly
attributed to the effect of A-FABP on metabolic deterioration.
In addition to its metabolic actions, A-FABP also plays a critical
role in the development of atherosclerosis through coordinating
macrophage cholesterol trafficking and inflammatory activity [26].
High levels of A-FABP were found in atherosclerotic lesions in
both mice and humans [26]. In the absence of A-FABP,
cholesterol trafficking was enhanced [26] and the capacity for
foam cell formation of macrophages was reduced significantly [7].
In addition, A-FABP can activate several key inflammatory
pathways. In A-FABP deficient macrophages, the IkB kinase –
NF-kB pathway is impaired, resulting in suppression of inflam-
matory function. Besides that, peroxisome proliferator-activated
receptor c and the liver X receptor a activity are enhanced,
leading to the suppressed transcription of several inflammatory
genes [27,28]. BMS309403, a specific A-FABP inhibitor, was
found to have remarkable impact on the inhibition of atheroscle-
rosis in the apo E
-/- mouse model on a western diet [9]. In clinical
studies, Yeung et al. found that serum A-FABP was an
independent determinant of carotid atherosclerosis as determined
by carotid intima-media thickness in Chinese women [12].
Miyoshi et al reported that A-FABP was independently associated
with coronary plaque burden measured by intravascular ultra-
sound in 125 CAD patients, and women had a greater impact than
in men [29]. Similarly in the present study, A-FABP not only
significantly elevated in CAD patients, but was closely associated
with the presence of CAD in women, independent of the influence
of the traditional risk factors. We further found a positive
correlation of serum A-FABP with the severity of coronary
atherosclerosis. Serum A-FABP concentration increased signifi-
cantly with the increasing number of stenotic vessels, which was in
Table 4. Correlations of A-FABP levels with anthropometric
parameters and biochemical indexes.
All Men Women
r P r P r P
Age 0.371 ,0.001 0.325 ,0.001 0.260 0.005
BMI 0.163 0.003 0.139 0.042 0.341 ,0.001
Waist
circumference
0.161 0.004 0.215 0.002 0.406 ,0.001
Systolic BP 0.057 NS 20.008 NS 0.127 NS
Diastolic BP 20.016 NS 20.039 NS 0.120 NS
FPG 0.152 0.005 0.142 0.036 0.155 NS
2hPG 0.127 0.022 0.161 0.020 0.222 0.018
HbA1c 0.214 ,0.001 0.313 ,0.001 0.163 NS
Fasting insulin 0.228 ,0.001 0.239 0.001 0.148 NS
HOMA-IR 0.240 ,0.001 0.333 ,0.001 0.404 ,0.001
TC 0.118 0.033 20.089 NS 0.152 NS
TG 0.077 NS 20.006 NS 0.131 NS
HDL-c 0.029 NS 20.163 0.018 20.021 NS
LDL-c 0.143 0.010 20.013 NS 0.218 0.019
Creatinine 0.171 0.002 0.436 ,0.001 0.409 ,0.001
GFR 20.294 ,0.001 20.370 ,0.001 20.298 0.002
hsCRP 0.168 0.002 0.136 0.048 0.298 0.001
NT-proBNP 0.278 ,0.001 0.280 ,0.001 0.242 0.022
BMI: body mass index; BP, blood pressure; FPG: fasting plasma glucose; 2hPG: 2-
h postchallenge glycemia; GFR: glomerular filtration rate; HbA1c: glycated
hemoglobin A1c; HDL-c: high density lipoprotein cholesterol; HOMA-IR:
homeostasis model assessment index of insulin resistance; hsCRP: high
sensitivity C-reactive protein; LDL-c: low density lipoprotein cholesterol; NT-




Table 5. Multiple stepwise regression analysis showing
variables independently associated with serum A-FABP.
Independent variables b S.E. Standardized b P
Gender (women) 0.311 0.038 0.460 ,0.001
Waist circumference 0.007 0.002 0.211 0.001
HbA1c
a 0.044 0.018 0.141 0.017
HOMA-IR
a 0.194 0.078 0.145 0.013
LDL-c 0.044 0.018 0.135 0.017
GFR
a 20.574 0.116 20.309 ,0.001
NT-proBNP
a 0.070 0.031 0.135 0.027
Variables included in the original model are age, gender, waist circumference,
FPG, 2hPG, HbA1c, HOMA-IR, lipid profile, GFR, hsCRP, and NT-proBNP.
aLogarithmically transformed before analysis.
GFR: glomerular filtration rate; HbA1c: glycated hemoglobin A1c; HOMA-IR:
homeostasis model assessment index of insulin resistance; LDL-c: low density
lipoprotein cholesterol; NT-proBNP: amino terminal pro-brain natriuretic
peptide.
doi:10.1371/journal.pone.0019115.t005
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[13,14]. Taken together, these observations suggest that serum A-
FABP may be a new marker for CAD and its circulating levels
may predict the extent and severity of coronary atherosclerosis in
women.
Another notable observation of this study is the independent
association between serum A-FABP and NT-proBNP, a hormone
secreted by cardiomyocytes following increased myocardial wall
stress and exerts favorable effects on heart such as promoting
vasodialation [30]. Circulating concentrations of NT-proBNP
have been used for the diagnosis/prognosis of heart failure. An
increasing body of evidence also suggests that myocardial ischemia
is a potent stimulus for BNP release, and NT-proBNP is a
promising biomarker for evaluating and predicting myocardial
ischemia in CAD [31]. A recent study reported that A-FABP
directly and acutely depressed contraction of cardiomyocytes by
attenuating intracellular Ca
2+ levels [32], suggesting a direct
bioactive role of A-FABP may exist in heart function. Therefore,
the elevated A-FABP may have an impact on the myocardial
synthesis of BNP through inducing coronary atherosclerosis or
directly influencing myocardial function. However, the mecha-
nism underlying the relationship between A-FABP and NT-
proBNP is not clear and remain to be further elucidated.
Furthermore, we also observed a positive association between
serum A-FABP and hsCRP. HsCRP is a well-known inflammatory
biomarker that can predict future cardiovascular events [33]. It
plays a direct pathogenic role in atherosclerosis by inducing
expression of nuclear factor-kB and adhesion molecules, stimulat-
ing macrophages to produce tissue factor, increasing the
expression and activity of plasminogen activator inhibitor-1 in
endothelia cells [34,35]. Therefore, our finding provided further
evidence of serum A-FABP in contributing to inflammatory
activity and atherosclerosis.
In the present study, we also found an independent negative
relationship between A-FABP and renal function as assessed by
GFR and serum creatinine, which is in accordance with a recent
study [36]. These observations support the notion that renal
filtration is a major route of elimination of A-FABP, which is
similar in several other adipokines like adiponectin and leptin.
This study has several limitations. First, the sample size was not
large enough. Second, the present study is cross-sectional, which
does not allow us to determine the cause-effect relationship
between A-FABP and the development of CAD. Further large
population-based prospective studies are needed to address
whether serum A-FABP is useful for predicting CAD. Further-
more, in order to obtain more accurate data about coronary
stenosis, we only recruited subjects admitted to hospital to undergo
coronary angiography, and most of these people have existing risk
factors of CAD, or already on intervention therapy. Whether our
findings can be replicated in the general population still needs to
be further confirmed.
In conclusion, we demonstrated that serum A-FABP was closely
associated with the presence and severity of CAD in Chinese
women. A-FABP may be an independent marker and predictor of
CAD. Our data, in conjunction with previous animal and clinical
studies, support the central role of A-FABP in the development of
the metabolic syndrome, diabetes and cardiovascular disease.
Further studies are warranted to evaluate whether A-FABP can be
used to predict the risk of CAD in larger study cohorts recruited
from the general population.
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